The Department of Energy is providing up to $2 million in fiscal year 2022 to fund university and national laboratory studies into the use of novel, medically relevant isotopes for use in pre-clinical and clinical medical trials, the DOE’s Office of Science announced on June 1.

This vial contains traces of actinium within a mixture of thorium and uranium. Photo: Isotek

An article recently published in Chemical & Engineering News describes TerraPower’s efforts to extract actinium-225, a radioisotope with therapeutic potential, from highly radioactive uranium-233 owned by the Department of Energy and slated for disposal. While others are working to ramp up production of Ac-225 by using a linear accelerator or cyclotron, TerraPower hopes to harvest between 200,000 and 600,000 doses a year from U-233 to increase the global supply.

The U.S. healthcare industry is warning that the COVID-19 pandemic may threaten supplies of the medical radioisotope molybdenum-99, whose decay product, technetium-99m, is considered the workhorse isotope in nuclear medicine for diagnostic imaging. The online magazine Radiology Business recently reported that the American Society of Nuclear Cardiology (ASNC) alerted its members on April 1 that it is monitoring supply shortages of Mo-99 “more closely than ever” during the pandemic.